Calprotectin I Serum as a Diagnostic Marker

Lower respiratory tract infection is the most common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Patients diagnosed with pneumonia in addition to an AECOPD experience more severe clinical and laboratory disease manifestations, increase in-hospital morbidity and worse outcome. Clinicians have sought for new biomarkers that together with clinical assessments can improve the diagnostic accuracy of pneumonia in patients with AECOPD.The aim of the present study is to compare the accuracy of calprotectin with procalcitonin (PCT), C-reactive protein (CRP) and white blood cell count (WBC).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Disease, Chronic Obstructive Chronic Disease Clinical Deterioration Disease Attributes Disease Progression Hypersensitivity Immune System Diseases Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Thoracic and Occupational Medicine

Trondheim, Trøndelag, 7006, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

clinically confirmed acute exacerbation of chronic obstructive pulmonary disorder (AECOPD)
COPD diagnosis previously confirmed by spirometry according to the GOLD criteria.

Exclusion criteria

known malignant disease
bronchiectasis
chronic bacterial colonisation of the airways
treatment with an immunosuppressive drug or long-term treatment with antibiotics.
not examined with a chest X-ray at admission

Treatment and study plan

Primary outcomes

Calprotectin concentration in serum

Time frame: Change in serum concentration from baseline to 48 hours

ELISA-kit (MRP8/14 ELISA)

Sponsors and collaborators

Lead sponsor

St. Olavs Hospital

Other

Collaborators

Norwegian University of Science and Technology

Registry information

Official study title

Calprotectin I in Serum as a Diagnostic Marker of Pneumonia in Patients Hospitalised With Acute COPD Exacerbation

Important dates

Study start: 2018
Primary completion: 2018
Study completion: 2018
First posted: Mar 22, 2018
Registry last updated: Sep 21, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed